184 related articles for article (PubMed ID: 7544852)
21. HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides.
Pezeshki AM; Azar GA; Mourad W; Routy JP; Boulassel MR; Denzin LK; Thibodeau J
Hum Immunol; 2013 Oct; 74(10):1280-7. PubMed ID: 23756162
[TBL] [Abstract][Full Text] [Related]
22. Binding of staphylococcal enterotoxin A to HLA-DR on B cell lines.
Fischer H; Dohlsten M; Lindvall M; Sjögren HO; Carlsson R
J Immunol; 1989 May; 142(9):3151-7. PubMed ID: 2785135
[TBL] [Abstract][Full Text] [Related]
23. Targeting of human cytotoxic T lymphocytes to MHC class II-expressing cells by staphylococcal enterotoxins.
Dohlsten M; Lando PA; Hedlund G; Trowsdale J; Kalland T
Immunology; 1990 Sep; 71(1):96-100. PubMed ID: 2210803
[TBL] [Abstract][Full Text] [Related]
24. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens.
Zhu X; Bavari S; Ulrich R; Sadegh-Nasseri S; Ferrone S; McHugh L; Mage M
Eur J Immunol; 1997 Aug; 27(8):1933-41. PubMed ID: 9295029
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxic T lymphocyte-dependent tumor growth inhibition by a vascular endothelial growth factor-superantigen conjugate.
Sun Q; Jiang S; Han B; Sun T; Li Z; Zhao L; Gao Q; Sun J
Biochem Biophys Res Commun; 2012 Nov; 427(4):711-7. PubMed ID: 23036194
[TBL] [Abstract][Full Text] [Related]
26. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Bohlen H; Manzke O; Patel B; Moldenhauer G; Dörken B; von Fliedner V; Diehl V; Tesch H
Cancer Res; 1993 Sep; 53(18):4310-4. PubMed ID: 7689932
[TBL] [Abstract][Full Text] [Related]
27. Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY.
Szöllósi J; Horejsí V; Bene L; Angelisová P; Damjanovich S
J Immunol; 1996 Oct; 157(7):2939-46. PubMed ID: 8816400
[TBL] [Abstract][Full Text] [Related]
28. Immune response during tumor therapy with antibody-superantigen fusion proteins.
Rosendahl A; Hansson J; Sundstedt A; Kalland T; Dohlsten M
Int J Cancer; 1996 Sep; 68(1):109-13. PubMed ID: 8895549
[TBL] [Abstract][Full Text] [Related]
29. Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice.
Dohlsten M; Björklund M; Sundstedt A; Hedlund G; Samson D; Kalland T
Immunology; 1993 Aug; 79(4):520-7. PubMed ID: 7691731
[TBL] [Abstract][Full Text] [Related]
30. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy.
Dohlsten M; Abrahmsén L; Björk P; Lando PA; Hedlund G; Forsberg G; Brodin T; Gascoigne NR; Förberg C; Lind P
Proc Natl Acad Sci U S A; 1994 Sep; 91(19):8945-9. PubMed ID: 8090750
[TBL] [Abstract][Full Text] [Related]
31. T-cell stimulation and cytokine release induced by staphylococcal enterotoxin A (SEA) and the SEAD227A mutant.
Holzer U; Orlikowsky T; Zehrer C; Bethge W; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Immunology; 1997 Jan; 90(1):74-80. PubMed ID: 9038715
[TBL] [Abstract][Full Text] [Related]
32. Identification of the antigenic epitopes in staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy.
Erlandsson E; Andersson K; Cavallin A; Nilsson A; Larsson-Lorek U; Niss U; Sjöberg A; Wallén-Ohman M; Antonsson P; Walse B; Forsberg G
J Mol Biol; 2003 Nov; 333(5):893-905. PubMed ID: 14583188
[TBL] [Abstract][Full Text] [Related]
33. Staphylococcal enterotoxin H displays unique MHC class II-binding properties.
Nilsson H; Björk P; Dohlsten M; Antonsson P
J Immunol; 1999 Dec; 163(12):6686-93. PubMed ID: 10586065
[TBL] [Abstract][Full Text] [Related]
34. Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells.
Wahlsten JL; Mills CD; Ramakrishnan S
J Immunol; 1998 Dec; 161(12):6761-7. PubMed ID: 9862706
[TBL] [Abstract][Full Text] [Related]
35. Human major histocompatibility complex class II-negative colon carcinoma cells present staphylococcal superantigens to cytotoxic T lymphocytes: evidence for a novel enterotoxin receptor.
Dohlsten M; Hedlund G; Segren S; Lando PA; Herrmann T; Kelly AP; Kalland T
Eur J Immunol; 1991 May; 21(5):1229-33. PubMed ID: 1645269
[TBL] [Abstract][Full Text] [Related]
36. Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway.
Kansas GS; Tedder TF
J Immunol; 1991 Dec; 147(12):4094-102. PubMed ID: 1721639
[TBL] [Abstract][Full Text] [Related]
37. Superantigen-induced human CD4+ helper/killer T cell phenomenon. Selective induction of Th1 helper/killer T cells and application to tumor immunotherapy.
Kuge S; Miura Y; Nakamura Y; Mitomi T; Habu S; Nishimura T
J Immunol; 1995 Feb; 154(4):1777-85. PubMed ID: 7836762
[TBL] [Abstract][Full Text] [Related]
38. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy.
Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS
Leukemia; 2003 Oct; 17(10):1973-80. PubMed ID: 14513047
[TBL] [Abstract][Full Text] [Related]
39. Mechanism of Staphylococcus aureus exotoxin A inhibition of Ig production by human B cells.
Moseley AB; Huston DP
J Immunol; 1991 Feb; 146(3):826-32. PubMed ID: 1988499
[TBL] [Abstract][Full Text] [Related]
40. Tumor-reactive superantigens suppress tumor growth in humanized SCID mice.
Lando PA; Dohlsten M; Ohlsson L; Kalland T
Int J Cancer; 1995 Aug; 62(4):466-71. PubMed ID: 7635573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
